App-Quantinova.ai

The use of DaT scan for diagnosis of Idiopathic Parkinson’s disease and Parkinson’s Plus syndromes in clinical practice (HEFT experience)

M. Awadh - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

The use of DaT-SPECT scanning in the differential diagnosis of Parkinsonism: Are guidelines being followed?

J. Carling - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

The use of smartphone task derived features to predict clinical scores in Parkinson’s Disease (PD)

C. Lo - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Tremor in motor neuron disease may be central rather than peripheral in origin

A. Latorre - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Movement disorders

N/A

Unilateral abnormal dopamine transporter (DaT) scans: Early indicator of Parkinson’s disease and degenerative Parkinsonism

N. Heng - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Dopamine hydrochloride

Using remotely collected data to identify Parkinson’s disease (PD) subtypes

T. Dominey - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Using saccades as an early test of levodopa treatment in Parkinson’s Disease

Z.J. Lu - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Levodopa

Using Vision to Predict Dementia in Parkinson’s Disease

L-A. Leyland - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Variation in the L-dopa motor response in pathologically confirmed Parkinson’s disease

V. Pitz - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Levodopa

Visual impairment and falls in Parkinson’s disease (PD)

N. Butt - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Age-Related Macular Degeneration

N/A

Vitamin B3 and Neurodevelopment in Parkinson’s Disease

A. Williams - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Nicotinamide

What makes a successful Phase 2 study: An evaluation of Parkinson’s neuroprotective trial design over the last 5 years

T. Dominey - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Who uses guidance techniques for abobotulinumtoxinA injections in the routine management of cervical dystonia?

V. Misra - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Cervical dystonia

AbobotulinumtoxinA

Wrist-worn accelerometer measures of activity by people with Parkinson’s during and following dance

R. Hadley - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

“Motor” DDS: is motor sensitization underestimated after STN-DBS?

M. Ciocca - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

A longitudinal PET study to assess the state of microglia activation in a Phase 2 study of Laquinimod as a treatment for Huntington’s disease (LEGATO-HD)

A.A Roussakis - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Huntington's disease

N/A

A New Web-Based Tapping Test for Measuring Distal Bradykinesia in Parkinson’s Disease

N. Akram - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

AT-20

A novel easily performed objective test of fine motor skill in handwriting and drawing to support diagnosing Parkinson’s disease

R. Zietsma - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

A Systematic Review of the Psychometric Properties of Psychosis Rating Scales in Neurodegenerative Conditions

P.S Malhotra - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Advance Care Planning in Complex Stage Parkinson’s Disease

M. Khwaja - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Filters

45280 Abstracts